The present invention lies in the field of visualization and quantification of immobilized targets in samples using immunochemical means. In particular, the invention relates to a method and reagents for detection, visualization and quantification of a molecular target in immunosiained histological samples using particular compositions of the target specific binding agent. Methods and compositions of the invention are suitable for any assay that uses a target visualization system in histological samples based on detection of the target by the target specific binding agent. The methods and compositions tire useful for evaluation of targets that are biomarkers of diseases in medical diagnostic.

Methods for treating nerve damage in a muscle, e.g., denervated muscle tissue (e.g., muscle damaged from traumatic injury), in a patient in need thereof featuring performing a pre-operative muscle biopsy on the denervated muscle tissue; making visible motor end plates (MEPs) in neuromuscular junctions (NMJs) in the biopsy; and performing a nerve transfer (e.g., partial radial nerve to axillary transfer) if (i) the MEPs shown in the biopsy persist and (ii) the MEPs shown in the biopsy retain their structures and exhibit certain morphometric properties. The nerve transfer helps regain neuromuscular function of the denervated muscle tissue. The biopsy may feature the use of two-photon microscopy. In certain embodiments, the method is performed at least 6 months after injury to the patient.

The present invention lies in the field of visualization and quantification of immobilized targets in samples using immunochemical means. In particular, the invention relates to a method and reagents for detection, visualization and quantification of a molecular target in immunostained histological samples using particular compositions of the target specific binding agent. Methods and compositions of the invention are suitable for any assay that uses a target visualization system in histological samples based on detection of the target by the target specific binding agent. The methods and compositions are useful for evaluation of targets that are biomarkers of diseases in medical diagnostic.

Compositions and methods for detecting the presence and/or amount of one or more analytes, including analytes such as drugs of abuse, are provided. The compositions include two or more analytes associated with a solid phase, e.g., a particle or a multiwell plate. The compositions and methods also allow the simultaneous, tandem, or serial determination of the presence and/or amount of two or more analytes of interest in a sample.

The present invention relates to a method for assessing respiratory viral infections, the method includes preparing one or more precision-cut human bronchial tissues; exposing a cilia-rich epithelium within the precision-cut human bronchial tissues to establish an ex vivo model of human bronchus for viral infections; assessing infectivity, tropism, and pathogenesis of one or more respiratory viruses in the ex vivo model; and providing a semi-quantitative and normalized approach to supplement data from the ex vivo model of human bronchus for pandemic risk assessment of the one or more respiratory viruses. The present invention involves micro-dissection of bronchial tissues to expose the cilia-rich epithelium for ex vivo virus infection, along with a semi-quantitative approach for analyzing virus tropism and replication competence.

The present disclosure provides high-performance immunoreagents for use in a variety of immunologic assays and other related techniques. The immunoreagents comprise a primary antibody and a bridging antigen, wherein the bridging antigen is recognized by a detectable secondary antibody with high affinity. Also provided are compositions comprising panels of immunoreagents specific for multiple different target antigens and compositions comprising pairs of primary immunoreagents and their complementary detectable secondary antibodies. The paired primary immunoreagents and secondary antibodies are useful in a variety of immunologic assays, particularly in highly multiplexed assays, where the structure of the bridging antigen is varied in tandem with variation in the detectable secondary antibody, such that a multiplicity of immunoreagents are provided that are capable of simultaneously detecting a multiplicity of target antigens in a single assay. Also provided are kits comprising the immunoreagents, methods of immunologic assay using the immunoreagents of the disclosure, and methods of preparation of the immunoreagents.

The present disclosure provides an application of non-phosphorylated ?-catenin protein in tumor cells as a biomarker for predicting the responsivity or sensitivity of tumor cells to wnt pathway inhibitors, a method of using non-phosphorylated ?-catenin protein in tumor cells as a biomarker to predict the responsivity or sensitivity of tumor cells to wnt pathway inhibitors, a method for treating tumor patients, a method for detecting the content of non-phosphorylated ?-catenin in tumor tissues or tumor cells, and a suitable wnt inhibitor.

The present invention generally relates to method for preparing a biological sample for use in an immunolabeling process. The invention also relates to corresponding kits for use in the immunolabeling process.

Methods of detecting and treating an epithelial carcinoma, such as pancreatic ductal adenocarcinoma cancer or bladder cancer, expressing antithrombin-binding heparan sulfate (HS.sup.AT) in a subject, comprising combining a biological sample of the subject containing HS.sup.AT with antithrombin and detecting binding of HS.sup.AT and the antithrombin, optionally determining that the antithrombin inhibits factor Xa.

Disclosed are systems and methods for labelling one or more morphological markers in a biological sample that are characteristic of one or more molecular features. In particular, system and methods are described for labelling one or more morphological markers in a biological sample with covalently deposited narrow band detectable moieties. Narrow band detectable moiety labelling of the one or more morphological markers permits higher order multiplexed assays due to conservation of available spectral bandwidth. Furthermore, as compared to conventional counterstaining methods, covalent deposition of one or more detectable moieties can provide flexibility and robustness with regard to the order in which biomarkers and morphological markers are labeled in a given staining protocol.